CR20210683A - Anticuerpos anti-angpt2 - Google Patents

Anticuerpos anti-angpt2

Info

Publication number
CR20210683A
CR20210683A CR20210683A CR20210683A CR20210683A CR 20210683 A CR20210683 A CR 20210683A CR 20210683 A CR20210683 A CR 20210683A CR 20210683 A CR20210683 A CR 20210683A CR 20210683 A CR20210683 A CR 20210683A
Authority
CR
Costa Rica
Prior art keywords
angpt2
angpt2 antibodies
antibodies
angiopoietin
therapeutic
Prior art date
Application number
CR20210683A
Other languages
English (en)
Inventor
Pankaj Gupta
Thierry Bouyssou
Michael Dziegelewski
Chao Zheng
Ryan Michael Fryer
Paul Nicklin
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CR20210683A publication Critical patent/CR20210683A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a anticuerpos neutralizantes anti-angiopoyetina 2 (ANGPT2) novedosos para métodos de tratamiento y diagnóstico y una composición en la que se usan.
CR20210683A 2019-06-27 2020-06-25 Anticuerpos anti-angpt2 CR20210683A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962867253P 2019-06-27 2019-06-27
US202063013022P 2020-04-21 2020-04-21
PCT/US2020/039477 WO2020264065A1 (en) 2019-06-27 2020-06-25 Anti-angpt2 antibodies

Publications (1)

Publication Number Publication Date
CR20210683A true CR20210683A (es) 2022-02-23

Family

ID=71662321

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20210683A CR20210683A (es) 2019-06-27 2020-06-25 Anticuerpos anti-angpt2

Country Status (20)

Country Link
US (2) US11396539B2 (es)
EP (1) EP3990489A1 (es)
JP (1) JP2022538062A (es)
KR (1) KR20220028032A (es)
CN (1) CN114080396B (es)
AU (1) AU2020308569A1 (es)
BR (1) BR112021024176A2 (es)
CA (1) CA3140071A1 (es)
CL (1) CL2021003367A1 (es)
CO (1) CO2021017414A2 (es)
CR (1) CR20210683A (es)
EC (1) ECSP22004680A (es)
IL (1) IL289160A (es)
JO (1) JOP20210339A1 (es)
MA (1) MA56394A (es)
MX (1) MX2021015743A (es)
PE (1) PE20220809A1 (es)
SA (1) SA521431223B1 (es)
TW (1) TW202115112A (es)
WO (1) WO2020264065A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202115112A (zh) * 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (es)
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4434173A (en) 1982-08-23 1984-02-28 Pfizer Inc. Bis-esters of 4,5-di(hydroxymethyl)-2-oxo-1,3-dioxole as antibacterial agents
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
RO118524B1 (ro) 1992-11-13 2003-06-30 Idec Pharmaceuticals Corp San Metoda pentru tratarea unei tulburari legata de celulele b
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US6037454A (en) 1996-11-27 2000-03-14 Genentech, Inc. Humanized anti-CD11a antibodies
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6455035B1 (en) * 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
WO2006068953A2 (en) * 2004-12-21 2006-06-29 Astrazeneca Ab Antibodies directed to angiopoietin-2 and uses thereof
US8133979B2 (en) 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
US20110227286A1 (en) * 2010-03-18 2011-09-22 Davies Janet L Board Game and Method of Playing the Same
US9575073B2 (en) * 2011-10-10 2017-02-21 Rutgers, The State University Of New Jersey Detection of high-risk intraductal papillary mucinous neoplasm and pancreatic adenocarcinoma
WO2013134516A1 (en) 2012-03-08 2013-09-12 Medimmune, Llc Methods of treatment with angiopoietin-2 antibodies
US9828422B2 (en) 2013-07-29 2017-11-28 Samsung Electronics Co., Ltd. Anti-Ang2 antibody
MX2016008099A (es) 2013-12-20 2016-10-13 Hoffmann La Roche Terapia combinada con un anticuerpo anti-ang2 y un agonista de cd40.
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
HUE053239T2 (hu) * 2014-11-19 2021-06-28 Axon Neuroscience Se Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
JP2020503843A (ja) * 2016-10-21 2020-02-06 アディマブ， エルエルシー 抗呼吸器合胞体ウイルス抗体、及び、それらの生成及び使用の方法
KR102078957B1 (ko) * 2017-09-29 2020-02-20 추가이 세이야쿠 가부시키가이샤 혈액 응고 제 viii 인자(fviii) 보인자 기능 대체 활성을 갖는 다중특이성 항원 결합 분자 및 당해 분자를 유효 성분으로서 함유하는 약학적 제제
TW202115112A (zh) * 2019-06-27 2021-04-16 德商百靈佳殷格翰國際股份有限公司 抗-angpt2抗體

Also Published As

Publication number Publication date
EP3990489A1 (en) 2022-05-04
AU2020308569A1 (en) 2021-12-02
CL2021003367A1 (es) 2022-10-07
KR20220028032A (ko) 2022-03-08
TW202115112A (zh) 2021-04-16
MA56394A (fr) 2022-05-04
CA3140071A1 (en) 2020-12-30
CN114080396A (zh) 2022-02-22
IL289160A (en) 2022-02-01
CN114080396B (zh) 2024-05-17
US20200407435A1 (en) 2020-12-31
BR112021024176A2 (pt) 2022-03-22
JOP20210339A1 (ar) 2023-01-30
JP2022538062A (ja) 2022-08-31
US20220363743A1 (en) 2022-11-17
SA521431223B1 (ar) 2024-04-21
ECSP22004680A (es) 2022-02-25
WO2020264065A1 (en) 2020-12-30
PE20220809A1 (es) 2022-05-20
MX2021015743A (es) 2022-01-27
US11396539B2 (en) 2022-07-26
CO2021017414A2 (es) 2022-01-17

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12021550690A1 (en) Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
ZA202004730B (en) Anti-claudin 18.2 antibodies and uses thereof
MX2020009366A (es) Anticuerpos anti-cd73 y usos de los mismos.
MX2018012757A (es) Anticuerpos agonistas que se unen a cd40 humana y usos de los mismos.
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
WO2018151821A8 (en) ANTI-ALPHA-SYNUCLEIN ANTIBODIES AND USES THEREOF
MX2021014286A (es) Proteinas multiespecificas.
PH12021550764A1 (en) Trem2 stabilizing antibodies
MX367661B (es) Anticuerpos anti-baff novedosos.
MX2021015337A (es) Anticuerpos multiespecificos de cadena pesada que se unen a cd22 y cd3.
PH12020552006A1 (en) Antibodies specific for cd3 and uses thereof
PH12019502694A1 (en) Anti-trkb antibodies
PH12018502275A1 (en) Interferon beta antibodies and uses thereof
MX2021004454A (es) Anticuerpos anti-sinucleina.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
MX2021006865A (es) Anticuerpos anti-alfa-sinucleina y usos de estos.
SA521431223B1 (ar) Angpt2 أجسام مضادة لـ
MX2022006145A (es) Anticuerpos trem2 y usos de estos.
MX2021005751A (es) Anticuerpos contra mucina 16 y métodos de uso de los mismos.
MX2020013923A (es) Anticuerpos anti molécula de adhesión celular l1 (l1cam) y usos de estos.
EA202290101A1 (ru) Антитела к angpt2
MX2021015922A (es) Proteínas quiméricas sintéticas estabilizadas y sus usos terapéuticos.
MX2022014974A (es) Anticuerpos anti-pd-1.